Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06971614 · ClinicalTrials.gov registry record · Phase 2
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
A Phase 2 study of Non-muscle Invasive Bladder Cancer, sponsored by ImmVira Pharma Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 2
- Study locations
NCT06971614: Recruiting Phase 2 study of Non-muscle Invasive Bladder Cancer, sponsored by ImmVira Pharma Co..
NCT06971614 is a Phase 2 study of Non-muscle Invasive Bladder Cancer that is actively recruiting participants, run by ImmVira Pharma Co.. The registered enrollment target is 160 participants, below the 221-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (28% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06971614, a Phase 2 study of Non-muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by ImmVira Pharma Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.
Conditions Studied
Interventions
- BIOLOGICAL T3011
Study Locations (2)
Arizona
- East Valley Urology Center - Queen Creek
Florida
- Florida Urology Partners, LLP - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2029-05-31 |
| Phase | Phase 2 |
What NCT06971614 shows while recruiting
NCT06971614 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which T3011 is the first listed.
NCT06971614 reports a single indexed study location in Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06971614 about?
NCT06971614 is a clinical study titled "A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC". This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.
What is the current status of trial NCT06971614?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-06-09. Estimated completion is 2029-05-31.
What conditions does trial NCT06971614 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.
What interventions are being tested in trial NCT06971614?
The interventions under investigation include: T3011 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06971614?
This trial is sponsored by ImmVira Pharma Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06971614 being conducted?
This trial has 2 study locations across Arizona, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06971614's enrollment target sits among peer trials
160 13th of 30 higher than 18 of 30 other Non-muscle Invasive Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-muscle Invasive Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
RECRUITING · Phase 2
-
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
RECRUITING · Phase 2
-
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
RECRUITING · Phase 2
-
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
COMPLETED · Phase 2
-
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI